MAP2K7 and hepatocellular carcinoma: Dasatinib inhibits the proliferation, adhesion, migration and invasion of HCC cells in vitro via inhibiting Src and affecting SFK/FAK and PI3K/PTEN/Akt signaling pathways, but not Ras/Raf/MEK/ERK and JAK/Stats pathways.